The patented cliff is here again, how should the enterprise lay out

Patent is an eternal topic of the pharmaceutical industry.

Following the "patent cliff" in 2012, the original pharmaceutical patent patent in the past two years has once again ushered in a small peak. Data show that the 2021 and 2022 patent -expired drugs were 38 and 29, respectively, involving many fields such as anti -infection, anti -tumor, and nervous system. How can the original research companies deal with the chase of the latecomers? How should Imitation pharmaceutical companies lay out and grab the opportunity?

On May 17, Jianzhi Bureau invited Sheng Yangyu, a researcher at the China Pharmaceutical Industry Information Center, Yan Xiaoyi, Director of Botate Intellectual Property, and Ma Qingwen, Minister of the Ministry of Pharmaceutical Law of Lunan Pharmaceutical Law, and Li Ying, Minister of Biomedicine, Hankun Law Firm. Discuss how to perform the topic of drug patent layout.

Sheng Yangxuan believes that when the patent -expired drug screening is screened, generic drug companies need to be deployed in advance. They choose drugs in 5 years or 10 years as a cycle, and have targeted products that are still blank in the domestic market. In addition, the status of drugs around the world, and patent distribution is also a factor that needs to be considered.

From the legal level, Li Ying focused on explaining the issue of "patent cliffs". She believes that the patent link system that has been landed in China at present can already "through peaceful means" instead of fierce lawsuits to solve the infringement of the original research drugs and generic drugs in the patented but not expired.

Ma Qingwen and Yan Xiaoyu shared the experience of how to carry out the patent layout of drugs from the corporate perspective. Ma Qingwen introduced that the institutional system is the cornerstone. If the enterprise does not have a good intellectual property security system, the topic of subsequent infringement analysis and patent layout are "air tower"; , R & D and other aspects.

### ## Pharmaceutical company#

- END -